Google search engine

HomeUncategorizedAmgen’s stock falls 4% as analysts say drug updates lag competitors

Amgen’s stock falls 4% as analysts say drug updates lag competitors

By launch-wire.com

25 September 2024

0

The biotech offered an update on two drugs in development, but analysts said they’re not as effective as existing treatments.

Previous article

Expect crypto bulls to flock back to this space now that the Fed is cutting rates

Next article

Why now may be a good time to take ‘opportunistic’ profits in gold and silver

RELATED ARTICLES

LEAVE A REPLY Cancel reply

Please enter your comment!

Please enter your name here

You have entered an incorrect email address!

Please enter your email address here

Most Popular

Recent Comments